PET/CT Skills Assessment | PET/CT SKILLS Assessment Questions with Verified Answers | 2025
PET/CT Benefits - ANSWER Assess treatment response, early diagnosis, staging, and restaging
in oncology, cardiology, and neurology.
PET Radiopharmaceuticals - ANSWER Include [18F]FDG, [18] Fluciclovine, and [68Ga]Ga-
citrate with short half-lives and biologically active components.
Normal FDG Biodistribution - ANSWER Malignant cells appear 'hot' on PET scans due to
increased glucose uptake, while normal uptake varies in different body organs.
Normal Variants in FDG Imaging - ANSWER Identify variations in FDG activity in different body
parts like vocal cords, thymus, brown fat, and GI tract.
FDG Contraindications - ANSWER Avoid FDG in diabetic patients with blood glucose above 200
mg/dL, insulin administration within 4 hours, to prevent artifacts.
Hypermetabolism - ANSWER Also known as FDG avidity, indicating increased metabolic
activity in cells.
Carbohydrate Metabolism - ANSWER Process breaking down glucose via glycolysis to provide
energy for cells.
Amino Acid Metabolism - ANSWER Radiolabeled amino acids like DOTA-TATE and Fluciclovine
target increased amino acid metabolism in tumor cells.
Factors Affecting SUV - ANSWER SUV influenced by lesion size, system resolution, time, and
must scan within a specific time window for accurate results.
, Standardized Uptake Value (SUV) - ANSWER Quantitative measure assessing metabolic
function in specific areas, with SUV >2.5 indicating suspicion for malignancy.
Target-to-Background Ratio - ANSWER Utilizes patient data, CT scans, and activity
measurements to evaluate activity concentrations in regions of interest.
Attenuation Correction - ANSWER Involves using CT scans, dose calibrators, and well counters
to correct for attenuation in PET imaging.
CT scan - ANSWER X-ray imaging for anatomical localization
Attenuation Correction (AC) - ANSWER Compensation for radiation absorption in CT for
accurate PET imaging
Loss of counts - ANSWER Decrease in detected events due to absorption or scattering
Image artifacts - ANSWER Irregularities in the image caused by attenuation
Hot Skin - ANSWER Prominent skin lesion visibility without attenuation correction
Positron Decay - ANSWER Proton to neutron conversion releasing a positron
FDG Production - ANSWER Accelerator-produced PET radionuclide
Decay Correction - ANSWER Adjusting administered dose based on decay rate
Collimator - ANSWER Device filtering gamma rays for image clarity
PET/CT Benefits - ANSWER Assess treatment response, early diagnosis, staging, and restaging
in oncology, cardiology, and neurology.
PET Radiopharmaceuticals - ANSWER Include [18F]FDG, [18] Fluciclovine, and [68Ga]Ga-
citrate with short half-lives and biologically active components.
Normal FDG Biodistribution - ANSWER Malignant cells appear 'hot' on PET scans due to
increased glucose uptake, while normal uptake varies in different body organs.
Normal Variants in FDG Imaging - ANSWER Identify variations in FDG activity in different body
parts like vocal cords, thymus, brown fat, and GI tract.
FDG Contraindications - ANSWER Avoid FDG in diabetic patients with blood glucose above 200
mg/dL, insulin administration within 4 hours, to prevent artifacts.
Hypermetabolism - ANSWER Also known as FDG avidity, indicating increased metabolic
activity in cells.
Carbohydrate Metabolism - ANSWER Process breaking down glucose via glycolysis to provide
energy for cells.
Amino Acid Metabolism - ANSWER Radiolabeled amino acids like DOTA-TATE and Fluciclovine
target increased amino acid metabolism in tumor cells.
Factors Affecting SUV - ANSWER SUV influenced by lesion size, system resolution, time, and
must scan within a specific time window for accurate results.
, Standardized Uptake Value (SUV) - ANSWER Quantitative measure assessing metabolic
function in specific areas, with SUV >2.5 indicating suspicion for malignancy.
Target-to-Background Ratio - ANSWER Utilizes patient data, CT scans, and activity
measurements to evaluate activity concentrations in regions of interest.
Attenuation Correction - ANSWER Involves using CT scans, dose calibrators, and well counters
to correct for attenuation in PET imaging.
CT scan - ANSWER X-ray imaging for anatomical localization
Attenuation Correction (AC) - ANSWER Compensation for radiation absorption in CT for
accurate PET imaging
Loss of counts - ANSWER Decrease in detected events due to absorption or scattering
Image artifacts - ANSWER Irregularities in the image caused by attenuation
Hot Skin - ANSWER Prominent skin lesion visibility without attenuation correction
Positron Decay - ANSWER Proton to neutron conversion releasing a positron
FDG Production - ANSWER Accelerator-produced PET radionuclide
Decay Correction - ANSWER Adjusting administered dose based on decay rate
Collimator - ANSWER Device filtering gamma rays for image clarity
